RFA-AI-23-023: International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $125,000 to the applicants described in the notice. Applications closed on May 23, 2025.
From the official notice on Grants.gov, last changed May 15, 2025. Checked November 7, 2026.
- Award ceiling$125,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$133,773
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AI-23-023 were run by National Institute of Allergy and Infectious Diseases (NIAID, 19 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-23-023 in the NIH Guide.
Key dates
| Posted | April 14, 2023 |
|---|---|
| Deadline | May 23, 2025 |
| Archived by Grants.gov | June 22, 2025 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $133,773; it allows up to $125,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission.
Funded under RFA-AI-23-023 so far
NIH funded 19 projects under RFA-AI-23-023 in fiscal 2024 to 2026, at 17 institutions. The median yearly award was $133,773.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-23-023 still open?
No. It closed on May 23, 2025.
Who can apply for International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)?
Closed May 23, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $125,000 each.
Who has been funded under RFA-AI-23-023?
NIH RePORTER lists 19 projects funded under RFA-AI-23-023 in fiscal 2024 to 2026, at 17 institutions. The most were at Institute/Research/Biotechnology FDN, Institute of Molecular /Cellular Biology, Medical Research Council of South Africa.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)